Result Number | Material Type | Add to My Shelf Action | Record Details and Options |
---|---|---|---|
1 |
Material Type: Standards
|
Atogepant for preventing migraineNICE Guidance, 2024Copyrights: © NICE 2024 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
|
2 |
Material Type: Standards
|
Selinexor with bortezomib and dexamethasone for previously treated multiple myelomaNICE Guidance, 2024Copyrights: © NICE 2024 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
|
3 |
Material Type: Standards
|
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19NICE Guidance, 2024Copyrights: © NICE 2024 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
|
4 |
Material Type: Standards
|
Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndromeNICE Guidance, 2024Copyrights: © NICE 2024 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
|
5 |
Material Type: Standards
|
Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and underNICE Guidance, 2024Copyrights: © NICE 2024 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
|
6 |
Material Type: Standards
|
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancerNICE Guidance, 2024Copyrights: © NICE 2024 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |
|
7 |
Material Type: Standards
|
Selinexor with dexamethasone for treating relapsed or refractory multiple myeloma after 4 or more treatmentsNICE Guidance, 2024Copyrights: © NICE 2024 All rights reserved. Subject to Notice of rightsDigital Resources/Online E-Resources |